Clinical Edit Criteria Proposal

Drug/Drug Class: Tindamax® Clinical Edit
Implementation Date: October 24, 2007
Prepared for: MO HealthNet Division

☐ New Criteria  ☒ Revision of Existing Criteria

Executive Summary
Purpose: Ensure appropriate utilization and control of Tindamax® (tinidazole tablets).

Tindamax® (tinidazole) is an antiprotozoal drug, which is oral therapy used to treat certain parasitic infections, including trichomoniasis, giardiasis, intestinal amebiasis, and amebic liver abscess. Tindamax® is a second-generation nitroimidazole comparable to metronidazole, a first-generation nitromidazole. As with metronidazole, it is advisable to take Tindamax® with food to minimize the incidence of epigastric discomfort and other gastrointestinal side effects. It is a single 2-gram dose that remains therapeutically active in patients for up to 48 hours after dosing.

Program-specific information:
- Tindamax®
- Tindamax®

Setting & Population: All patients.

Type of Criteria:
- ☐ Increased risk of ADE
- ☐ Non-Preferred Agent
- ☒ Appropriate Indications
- ☐

Data Sources:
- ☐ Only administrative databases
- ☒ Databases + Prescriber-supplied

Drug

<table>
<thead>
<tr>
<th>Strength &amp; Dosage Form</th>
<th>Cost per Tab (WAC)</th>
</tr>
</thead>
<tbody>
<tr>
<td>250mg tab</td>
<td>$2.35</td>
</tr>
<tr>
<td>500mg tab</td>
<td>$4.10</td>
</tr>
</tbody>
</table>
Setting & Population

- Drug for review: Tindamax® (tinidazole tablets)
- Age range: All ages
- Gender: Male and female

Approval Criteria

- Diagnosis of one of the following:
  1. Bacterial Vaginosis
  2. Trichomoniasis
  3. Giardiasis
  4. Intestinal Amebiasis
  5. Amebic Liver Abscess
- Documented trial and failure on metronidazole
- Documented ADE/ADR to metronidazole

Denial Criteria

- Failure to meet approval criteria.

References:

3. USPDI, Micromedex; 2005.